Literature DB >> 11880391

Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay.

Eric Q Konnick1, Maria Erali, Edward R Ashwood, David R Hillyard.   

Abstract

The COBAS Amplicor Hepatitis C Virus (HCV) Monitor assay, version 2.0, which reports in international units per milliliter, was compared to the assay reported in copies per milliliter by analyzing dilution series and clinical plasma samples by both methods. In addition, the Amplicor international unit assay was compared to the National Genetics Institute HCV Superquant assay. The dilution series ranged from <100 to 5,000,000 HCV RNA copies/ml and consisted of 32 points, assayed in triplicate in each assay. Thirty clinical samples ranging from 1,000 to 1,000,000 HCV RNA copies/ml were assayed in duplicate. Deming regression analysis comparing the Amplicor HCV RNA international units-per-milliliter and copies-per-milliliter assays was calculated as follows: (Amplicor international units per milliliter) = 1.030(Amplicor copies per milliliter) - 0.392; R(2) = 0.981; n = 28; S(y/x) (standard error of the estimate) = 0.129. The linearity of the Amplicor international units-per-milliliter assay was as follows: observed = 0.886(expected) + 0.437; R(2) = 0.983; n = 30. The linearity of the Superquant assay was as follows: observed= 0.918 (expected) + 0.436; R(2) = 0.986; n = 32. Deming regression analysis comparing the Amplicor and Superquant assays was calculated as follows: Superquant = 1.066(Amplicor) - 0.0197; R(2) = 0.908; S(y/x) = 0.308; n = 28. The Amplicor and Superquant assays were linear through the range of 600 to 600,000 IU of HCV RNA/ml and approximately 300 to 5,000,000 HCV RNA copies/ml, respectively. The narrow range of the Amplicor assay means that some samples will require dilution and retesting for accurate quantification above 600,000 IU of HCV RNA/ml. The Amplicor and Superquant assays agreed well within the range of 600 to 600,000 IU of HCV RNA/ml (approximately 1,000 to approximately 1,000,000 HCV RNA copies/ml). Overall, the Amplicor and Superquant assays agree well, and results obtained in one assay could be expected to compare well with results from the other when reported in copies per milliliter.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880391      PMCID: PMC120227          DOI: 10.1128/JCM.40.3.768-773.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays.

Authors:  C Sarrazin; G Teuber; R Kokka; H Rabenau; S Zeuzem
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

Review 2.  Standards of treatment in chronic hepatitis C.

Authors:  R G Gish
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

3.  COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR.

Authors:  N DiDomenico; H Link; R Knobel; T Caratsch; W Weschler; Z G Loewy; M Rosenstraus
Journal:  Clin Chem       Date:  1996-12       Impact factor: 8.327

Review 4.  Diagnosis of hepatitis C.

Authors:  A S Lok; N T Gunaratnam
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

5.  Comparison of quantitative HCV RNA assays in chronic hepatitis C.

Authors:  S Jacob; D Baudy; E Jones; L Xu; A Mason; F Regenstein; R P Perrillo
Journal:  Am J Clin Pathol       Date:  1997-03       Impact factor: 2.493

6.  Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Authors:  S C Lee; A Antony; N Lee; J Leibow; J Q Yang; S Soviero; K Gutekunst; M Rosenstraus
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

7.  Performance characteristics of the COBAS AMPLICOR hepatitis C virus MONITOR Test, version 2.0.

Authors:  M Erali; E R Ashwood; D R Hillyard
Journal:  Am J Clin Pathol       Date:  2000-08       Impact factor: 2.493

8.  Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications.

Authors:  D R Gretch; C dela Rosa; R L Carithers; R A Willson; B Williams; L Corey
Journal:  Ann Intern Med       Date:  1995-09-01       Impact factor: 25.391

9.  Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.

Authors:  G Yamada; M Takatani; F Kishi; M Takahashi; T Doi; T Tsuji; S Shin; M Tanno; M S Urdea; J A Kolberg
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

10.  Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin.

Authors:  M J Tong; S J Hwang; M Lefkowitz; S D Lee; R L Co; A Conrad; P Schmid; K J Lo
Journal:  J Gastroenterol Hepatol       Date:  1994 Nov-Dec       Impact factor: 4.029

View more
  7 in total

1.  Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Authors:  Chihiro Morishima; Minjun Chung; Ka Wing Ng; Donald J Brambilla; David R Gretch
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.

Authors:  Micaela B Reddy; Peter N Morcos; Sophie Le Pogam; Ying Ou; Karl Frank; Thierry Lave; Patrick Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

3.  Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays.

Authors:  Eric Q Konnick; Sheri M Williams; Edward R Ashwood; David R Hillyard
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

4.  Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus.

Authors:  M Fernanda Sábato; Mitchell L Shiffman; Michael R Langley; David S Wilkinson; Andrea Ferreira-Gonzalez
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

Review 5.  Update on hepatitis B and C virus diagnosis.

Authors:  Livia Melo Villar; Helena Medina Cruz; Jakeline Ribeiro Barbosa; Cristianne Sousa Bezerra; Moyra Machado Portilho; Letícia de Paula Scalioni
Journal:  World J Virol       Date:  2015-11-12

6.  Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays.

Authors:  Ronald E Engle; Rodney S Russell; Robert H Purcell; Jens Bukh
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

7.  Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent.

Authors:  James M Barbeau; Jennifer Goforth; Angela M Caliendo; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.